eisai
(2)
Craig Hopkinson Turns Deep Science Into Medicines That Reach People
A doctor by training who now runs research, development and medical affairs at one of neuroscience's most watched biopharma companies - and keeps the patient at the center of every decision.
Michael Shih
Michael Shih is the Chief Executive Officer of NeoPhore Ltd, a London-based small molecule neoantigen immuno-oncology company developing first-in-class drugs that target the DNA mismatch repair (MMR) pathway to make cancers more visible to the immune system. An attorney by training with degrees in biology, he spent nearly two decades structuring biotech deals before sitting in the chief executive's chair, with senior business development and corporate development roles at Kite Pharma, Biogen, Sanofi, Epizyme, Forest Laboratories, Kastle Therapeutics and Eisai. He took the helm at NeoPhore in December 2024, right after the company closed an oversubscribed Series B round backed by Bristol Myers Squibb.